Journal
STATISTICAL METHODS IN MEDICAL RESEARCH
Volume 17, Issue 5, Pages 515-518Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0962280207081862
Keywords
-
Ask authors/readers for more resources
There has been interest in using progression-free survival as a surrogate endpoint for overall survival in oncology clinical trials. In order to objectively define this endpoint, clear understanding of what progression means, how it is measured and what its implications are need to be discussed. This article discusses some regulatory aspects of using progression-free survival as an endpoint.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available